DOTA-JR11

O=C(N[C@@H](C(N[C@H](C(N[C@@](C(N[C@@H](CSSC[C@H](C(N1)=O)NC([C@@H](NC(CN2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)=O)CC3=CC=C(C=C3)Cl)=O)C(N[C@@H](C(N)=O)CC4=CC=C(C=C4)O)=O)=O)([H])[C@H](O)C)=O)CCCCN)=O)CC5=CC=C(C=C5)NC(N)=O)[C@@H]1CC6=CC=C(C=C6)NC([C@@H]7CC(NC(N7)=O)=O)=O

[1]Krebs S, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020 Dec;47 (13) :3047-3057.|[2]Xie Q, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021 Sep;48 (10) :3129-3140.